-
Zhang Zhikuan, former secretary of the party group and director of the Beijing Food and Drug Administration, was investigated
Time of Update: 2022-04-21
On March 27, the official website of the Central Commission for Discipline Inspection and the State Supervision Commission announced that according to the Beijing Municipal Commission for Discipline Inspection: Zhang Zhikuan, the former Secretary of the Party Group and Director of the Beijing Food and Drug Administration, was suspected of serious violations of discipline and law, and is currently undergoing disciplinary review and supervision investigation .
-
Continue to promote medical reform to reduce the burden of medical treatment for the masses
Time of Update: 2022-04-21
On January 1 this year, the new version of the National Medical Insurance Catalog was implemented, and 67 new drugs were added through negotiation, with an average price reduction of 62%, covering the needs for drugs such as tumors, chronic diseases, and rare diseases .
-
More than half of patients reduce disease severity by at least 75% Lilly IL-13 antibody phase 3 clinical results are positive
Time of Update: 2022-04-21
Eli Lilly and Company announced that its investigational IL-13 inhibitor, lebrikizumab, as a monotherapy, has achieved positive results in a pivotal Phase 3 clinical trial in patients with moderate-to-severe atopic dermatitis .
"References:[1] Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies.
-
Medicine machine man, find a new outlet?
Time of Update: 2022-04-21
With the rapid development of the biopharmaceutical industry, it is expected that the market share of high-end pharmaceutical equipment will increase to 32% by 2024 .
-
This multinational pharmaceutical company has another high-level change!
Time of Update: 2022-04-21
Recently, AstraZeneca issued an internal announcement: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons .
-
In order to accelerate innovation, domestic and foreign pharmaceutical companies have set off a new round of cooperation
Time of Update: 2022-04-21
Roche has announced a partnership with Bristol-Myers Squibb (BMS) to leverage two innovative digital pathology algorithms to support advancements in pathology detection in clinical trials .
In addition, Aide Bio and the French pharmaceutical company Pierre Fabre (Pierre Fabre Group) also reached a strategic cooperation in companion diagnostics in February .
-
Pharmaceutical companies have accelerated the process of commercialization and enhanced the ability of "hematopoietic"
Time of Update: 2022-04-20
The announcement also pointed out that at the same time as the new drug was launched, TOT BIOPHARM and domestic pharmaceutical companies carried out strategic cooperation in market promotion, promoted the process of product commercialization, and improved the availability of drugs .
-
China Biopharma's selective RET inhibitor approved for clinical use
Time of Update: 2022-04-20
Article source: Medical Cube InfoOn March 29, Sino Biopharmaceutical announced that the Group's self-developed Class 1 anti-tumor innovative drug "FHND5071" was approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of advanced solid tumors .
-
State Food and Drug Administration: It is clarified that some medical beauty products are managed as medical devices
Time of Update: 2022-04-20
The "Announcement" pointed out that, except for the radio frequency therapeutic apparatus and radio frequency skin therapeutic apparatus, other products are implemented from the date of the "Announcement" .
-
Lipid-lowering drug introduced by Eddingpharm was approved in Hong Kong, China
Time of Update: 2022-04-20
On March 29, Eddingpharm announced that the new drug marketing application of Eicosapentaenoic acid ethyl ester capsules (trade name Vascepa) for reducing the risk of cardiovascular events has been approved in Hong Kong, China.
-
The undercurrent of the pharmaceutical talent market is bringing about these changes
Time of Update: 2022-04-20
On March 28, Simcere announced the appointment of Danny Chen as the senior vice president of the group, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the Beijing Innovation Center's research and development team to enhance Simcere's capabilities in the field of central nervous system therapy.
-
PD-(L)1 competition continues to intensify, where is the way out for local pharmaceutical companies?
Time of Update: 2022-04-20
Recently, Henlius announced that its self-developed innovative biopharmaceutical PD-1 inhibitor H drug-Hanszoid® (generic name: slulimumab injection) was officially approved by the State Food and Drug Administration for use in Indications for adults with advanced solid tumors with unresectable or metastatic microsatellite instability-high (MSI-H) who have failed previous standard therapy .
-
The inclusion of innovative drugs in medical insurance has become a catalyst for high volume, and a large number of pharmaceutical companies have accelerated their deployment
Time of Update: 2022-04-20
It is reported that as early as November 5, 2021, the third quarterly report disclosed by BeiGene showed that the company is preparing for the upcoming national medical insurance drug catalog negotiation for eligible products, including the addition of first-line treatment for non-squamous non-small cell lung cancer.
-
The outbreak of the domestic biopharmaceutical industry, the development of the pharmaceutical equipment industry will enter a new spring
Time of Update: 2022-04-20
The global biopharmaceutical market size is expected to rise from US$202 billion in 2016 to US$326 billion in 2022, with a compound annual growth rate of 8.
Frost & Sullivan expects the global equipment and consumables market to maintain a growth rate of 8%-10% in the next five years .
-
Ministry of Ecology and Environment: my country's medical waste disposal is Nissan and Nissan
Time of Update: 2022-04-20
The Ministry of Ecology and Environment held a regular press conference this morning (March 30) . According to the Ministry of Ecology and Environment, since the recent outbreak of localized local
-
4 pharmaceutical companies reported good annual results, and 1 traditional Chinese medicine company's net profit increased by over 900%
Time of Update: 2022-04-20
It is reported that the main reason for the increase in performance is that in 2021, China Resources Sanjiu will continue to carry out innovation, transformation and upgrading, strengthen brand and channel construction, increase innovation investment, improve operation quality and efficiency, stabilize industry position, and achieve double growth in revenue and net profit .
-
The Shanghai Municipal People's Government issued policies and measures to fight the epidemic to help enterprises promote development
Time of Update: 2022-04-20
Promote government financing guarantee institutions to provide financing and credit enhancement support for eligible micro, small and medium-sized enterprises and individual industrial and commercial households, perform compensatory responsibilities in a timely manner in accordance with the law, help enterprises that have been greatly affected by the epidemic to renew their insurance and renew loans, and increase support for those affected by the epidemic.
-
The State Food and Drug Administration has approved 20 new coronavirus antigen detection reagents
Time of Update: 2022-04-20
(Finish) On March 29, after review by the State Food and Drug Administration, a new coronavirus antigen detection reagent product was approved .
(Finish) On March 29, after review by the State Food and Drug Administration, a new coronavirus antigen detection reagent product was approved .
-
Hainan Haiyao chairman Pan Dazhong retired and Wang Jianping took over
Time of Update: 2022-04-20
On March 29, Hainan Haiyao announced that the board of directors of the company received a written resignation application report from the company's chairman Pan Dazhong on March 26, 2022.
-
The market of 600 million ushered in the approval of the new dosage form of Heyi Pharmaceutical's lidocaine hydrochloride ophthalmic gel
Time of Update: 2022-04-20
Data source: Minet database, company announcement On March 24, the official website of the State Food and Drug Administration showed that the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical was approved for marketing, which was the first lidocaine ophthalmic gel in China .
